Lexaria Bioscience Corp. will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14-16, 2026, in New York City. CEO Richard Christopher will deliver a company presentation and hold one-on-one investor meetings. The event highlights Lexaria's patented DehydraTECH oral drug delivery technology, which enhances drug absorption and effectiveness. This participation aims to engage accredited investors and showcase Lexaria's innovation and growth potential.
Remittix is starting a test of its Earn platform, offering 100 participants weekly payouts with targeted yields of 18-22% APY on ETH, USDT, and USDC deposits, plus matching RTX token gifts. This move expands Remittix's PayFi ecosystem, which connects...
Stock futures are expected to begin trading on Sunday as investors await the Federal Reserve's upcoming meeting to decide on interest rate changes. This decision is crucial as it will influence market direction amid a busy week of earnings reports fr...
On October 25, Avalanche blockchain's block time was measured at 990 milliseconds over a one-hour period, with a finality time of two seconds. These metrics indicate the network's speed and efficiency in processing transactions. However, the one-hour...
Amkor Technology, Inc. is reaffirmed as a Buy with a revised price target of $55, reflecting a more cautious valuation amid stronger business fundamentals. The company's gross margin is expected to improve from 14.2% in Q1 to nearly 19% by Q3, driven...
Stacks co-founder Muneeb Ali highlighted that adopting quantum-resistant signatures for Bitcoin could reduce its block capacity by about tenfold, from around 4,200 transactions per block to as few as 84, depending on the signature size used. This red...
